Cargando…
Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study
BACKGROUND: The treatment of children with multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as IVIG and steroids. Anakinra, an interleukin-1 receptor inhibitor, has also been used, but its effectiveness is not established...
Autores principales: | Akkoyun, Esra B., Most, Zachary, Katragadda, Harita, Yu, Andrew, Nassi, Lorien, Oakman, Nicole, Ginsburg, Sarah, Maamari, Mia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666339/ https://www.ncbi.nlm.nih.gov/pubmed/37996856 http://dx.doi.org/10.1186/s12969-023-00924-6 |
Ejemplares similares
-
Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Bhat, Chandrika S., et al.
Publicado: (2021) -
Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19
por: Çaǧlayan, Şengül, et al.
Publicado: (2022) -
Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
por: Alolayan, Abdulaziz, et al.
Publicado: (2023) -
Tocilizumab versus anakinra in COVID-19: results from propensity score matching
por: Arcani, Robin, et al.
Publicado: (2023) -
Efficacy of anakinra on rebound of multisystem inflammatory syndrome
por: Brisca, Giacomo, et al.
Publicado: (2022)